Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management

M. Gambuzza, N. Licata, E. Palella, D. Celi, V. Foti Cuzzola, D. Italiano, S. Marino, P. Bramanti

Research output: Contribution to journalArticle

Abstract

Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalJournal of Neuroimmunology
Volume239
Issue number1-2
DOIs
Publication statusPublished - Oct 28 2011

Fingerprint

Toll-Like Receptors
Multiple Sclerosis
Autoimmune Experimental Encephalomyelitis
Therapeutics
Autoimmune Diseases
Proteins
Genes

Keywords

  • Innovative therapeutics
  • Multiple sclerosis
  • Receptor-targeting
  • Toll-like receptors

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Targeting Toll-like receptors : Emerging therapeutics for multiple sclerosis management. / Gambuzza, M.; Licata, N.; Palella, E.; Celi, D.; Foti Cuzzola, V.; Italiano, D.; Marino, S.; Bramanti, P.

In: Journal of Neuroimmunology, Vol. 239, No. 1-2, 28.10.2011, p. 1-12.

Research output: Contribution to journalArticle

Gambuzza M, Licata N, Palella E, Celi D, Foti Cuzzola V, Italiano D et al. Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management. Journal of Neuroimmunology. 2011 Oct 28;239(1-2):1-12. https://doi.org/10.1016/j.jneuroim.2011.08.010
Gambuzza, M. ; Licata, N. ; Palella, E. ; Celi, D. ; Foti Cuzzola, V. ; Italiano, D. ; Marino, S. ; Bramanti, P. / Targeting Toll-like receptors : Emerging therapeutics for multiple sclerosis management. In: Journal of Neuroimmunology. 2011 ; Vol. 239, No. 1-2. pp. 1-12.
@article{d4198abfc72346b08b871bb8f434101c,
title = "Targeting Toll-like receptors: Emerging therapeutics for multiple sclerosis management",
abstract = "Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.",
keywords = "Innovative therapeutics, Multiple sclerosis, Receptor-targeting, Toll-like receptors",
author = "M. Gambuzza and N. Licata and E. Palella and D. Celi and {Foti Cuzzola}, V. and D. Italiano and S. Marino and P. Bramanti",
year = "2011",
month = "10",
day = "28",
doi = "10.1016/j.jneuroim.2011.08.010",
language = "English",
volume = "239",
pages = "1--12",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Targeting Toll-like receptors

T2 - Emerging therapeutics for multiple sclerosis management

AU - Gambuzza, M.

AU - Licata, N.

AU - Palella, E.

AU - Celi, D.

AU - Foti Cuzzola, V.

AU - Italiano, D.

AU - Marino, S.

AU - Bramanti, P.

PY - 2011/10/28

Y1 - 2011/10/28

N2 - Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.

AB - Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.

KW - Innovative therapeutics

KW - Multiple sclerosis

KW - Receptor-targeting

KW - Toll-like receptors

UR - http://www.scopus.com/inward/record.url?scp=80054934482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054934482&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2011.08.010

DO - 10.1016/j.jneuroim.2011.08.010

M3 - Article

C2 - 21889214

AN - SCOPUS:80054934482

VL - 239

SP - 1

EP - 12

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -